Milestone Pharma Says New Data Analyses Of Investigational Product For PSVT, Etripamil Nasal Spray, Consistently Showed Efficacy And Favorable Safety Profile Across Multiple Studies Comprising Global Development Program

Author: Benzinga Newsdesk | November 03, 2025 08:11am

Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that new data analyses surrounding its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT), etripamil nasal spray, consistently showed efficacy and a favorable safety profile across multiple studies comprising the global development program. The poster, "Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia (PSVT) Across Multiple Clinical Trials," will be presented on Monday, November 10 (10:30–11:30 AM CST) at the American Heart Association Scientific Sessions 2025, in New Orleans, La. The data will be presented by James Ip, M.D., Professor of Medicine and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Department of Medicine, New York Weill Cornell-Presbyterian Hospital.

Posted In: MIST